Wilder,
The discussion of the preclinical candidates did sound very sexy, and the I expect the announcement of their next candidate (soon) should give the stock a boost. But I didn't come away from the Goldman Sachs presentation with a negative take on T67, particularly given that they are focusing on liver cancer. Goeddel pointed out that there is currently a very poor prognosis for HCC with no approved chemotherapy. During the last conference call, they mentioned that in their Phase II for T67 they had used a drastically reduced dosage for HCC patients. Since they had a very good safety profile, they felt confident that they could increase the dosage and show greater efficacy. Given the condition, I think they have a reasonable chance of getting Fast Track designation and a good chance of getting approval. With about a million cases of HCC per year, it could be very big. And T607 may turn out to be even better.
One of the the positives around TLRK's candidates is that they seem to have a good grasp of how they work, which I think makes the drugs more comprehensible and less black box for those reviewing them. And hopefully, their gene regulation approach will have good efficacy/side effect profiles. As Goeddel said, they are going for drugs with blockbuster potential. So if even a few make it, that may be enough to propel the company to major pharmaceutical status.
As for averaging down, if it makes sense to the CEO and the CFO I suppose it's OK for me, too. |
